Want to see ATTO full AI Analyst Report?
Top Page
Attovia Therapeutics, Inc.
(NASDAQ:ATTO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$18.00
▼(-29.55% Downside)
Action:N/A
Date:09/22/26
ATTO scores below average primarily due to very large losses and heavy ongoing cash burn, which elevate funding and dilution risk despite a relatively strong, low-debt balance sheet. Technical indicators are mixed and do not provide a strong bullish backdrop, while valuation is constrained by a negative P/E and the absence of a dividend yield.
Positive Factors
Low financial leverage
The substantial equity base relative to debt provides financial flexibility and limits near-term leverage pressure. This supportive capital structure may help Attovia absorb operating losses and preserve strategic options while it develops its business, although it does not eliminate the need for future financing.
Negative Factors
Extremely weak profitability
The very large loss compared with current revenue shows that Attovia’s cost base substantially exceeds its present operating scale. Persistent losses can consume shareholder capital and make progress toward sustainable earnings dependent on significant revenue growth or expense reduction.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
The substantial equity base relative to debt provides financial flexibility and limits near-term leverage pressure. This supportive capital structure may help Attovia absorb operating losses and preserve strategic options while it develops its business, although it does not eliminate the need for future financing.
Read all positive factors
Attovia Therapeutics, Inc. (ATTO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$950.92M
Dividend Yield3.4%
Average Volume (3M)281.68K
Price to Earnings (P/E)―
Beta (1Y)2.27
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees44
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,651,260
10 Day Avg. Volume372,134
30 Day Avg. Volume281,679
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)6.25
Price to Sales (P/S)698.03
P/FCF Ratio-15.32
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$39.75Price Target Upside55.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Attovia Therapeutics, Inc. Business Overview & Revenue Model
Company Description
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for th...
Attovia Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 450.00K | 1.35M | 0.00 | 1.45B | 1.41B | 1.71B |
| Gross Profit | -38.00K | 546.00K | -313.00K | 1.36B | 1.34B | 1.64B |
| EBITDA | -41.27M | -66.36M | -41.24M | 232.70M | 176.90M | 204.40M |
| Net Income | -39.34M | -60.63M | -39.80M | -90.20M | -46.80M | -80.70M |
Balance Sheet | ||||||
| Total Assets | 128.35M | 165.89M | 76.72M | 1.10B | 1.19B | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 115.13M | 152.27M | 69.32M | 129.57M | 210.15M | 125.80M |
| Total Debt | 4.33M | 5.26M | 0.00 | 718.28M | 726.58M | 720.61M |
| Total Liabilities | 15.58M | 15.10M | 14.59M | 1.11B | 1.07B | 1.12B |
| Stockholders Equity | 112.77M | 150.79M | 62.13M | -10.19M | 119.09M | 207.02M |
Cash Flow | ||||||
| Free Cash Flow | -35.29M | -61.51M | -36.81M | -5.80M | 90.00M | 6.30M |
| Operating Cash Flow | -34.93M | -59.20M | -35.03M | 42.30M | 128.20M | 46.40M |
| Investing Cash Flow | 29.36M | -73.45M | -39.80M | -50.50M | -38.20M | -56.00M |
| Financing Cash Flow | -1.80M | 142.01M | 82.75M | -58.20M | -300.00K | 5.10M |
Attovia Therapeutics, Inc. Risk Analysis
Attovia Therapeutics, Inc. disclosed 89 risk factors in its most recent earnings report. Attovia Therapeutics, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Attovia Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.61B | 7.52 | 2515.23% | ― | 92.92% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $1.14B | -3.35 | -82.68% | ― | ― | -37.48% | |
46 Neutral | $950.92M | -19.91 | -32.05% | 3.40% | ― | ― | |
46 Neutral | $432.19M | -3.83 | -54.98% | ― | ― | -65.84% | |
46 Neutral | $348.40M | -3.10 | -62.63% | ― | ― | ― | |
44 Neutral | $1.08B | -1.96 | -102.97% | ― | -63.11% | 15.36% |
* General Sector Average
ATTO
Attovia Therapeutics, Inc.
18.52
-3.38
-15.43%
ANAB
AnaptysBio
50.77
36.01
244.04%
MLTX
MoonLake Immunotherapeutics
12.90
-41.04
-76.08%
ZURA
Zura Bio
4.33
2.04
89.08%
ALMS
Alumis Inc.
7.44
3.30
79.71%
EVMN
Evommune, Inc.
8.77
-11.46
-56.65%
Attovia Therapeutics, Inc. Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Attovia adopts new charter and bylaws post-IPO
Neutral
Aug 6, 2026
On August 6, 2026, Attovia Therapeutics, Inc. filed an Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, and its Amended and Restated Bylaws became effective in connection with the closing of its initial publi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.